Investigational Therapies1

27

TOTAL MOLECULES

Phase III: 7 molecules

Phase II: 9 molecules

Phase I: 26 molecules

Select platforms, tumor types, and/or phases below to learn more.

Learn more about Genentech's investigational therapies. Click to expand.

Tumor types
Development platforms
Phases

The compounds and their uses mentioned on this website are investigational and have not been approved by the US Food and Drug Administration. Efficacy and safety have not been established. The information presented should not be construed as a recommendation for use. The relevance of findings in preclinical studies to humans is currently being evaluated.

Phase III

  • Hematology
  • Small Molecules

Ipatasertib
(AKT inhibitor)

(GDC-0068, RG7440)a

Find out more about how ipatasertib, an Akt inhibitor, is proposed to work.

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Small Molecules

Atezolizumab
(anti-PDL1 MAb)

(RG7446)

 

  • Gastrointestinal
  • Genitourinary
  • Gynecologic
  • Head and Neck
  • Hematology
  • Melanoma
  • Solid Tumor
  • Monoclonal Antibodies

Bevacizumab

(anti-VEGF MAb)

 

  • Gastrointestinal
  • Monoclonal Antibodies

Entrectinib
(ROS1/TRK inhibitor)

(RXDX-101, RG6268)b

 

  • Lung
  • Small Molecules

Pertuzumab + trastuzumab fixed-dose combination SC
(anti-HER2 MAbs)

(RG6264)

 

  • Breast
  • Monoclonal Antibodies

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)d

 

  • Hematology
  • Small Molecules

Phase II

  • Hematology
  • Small Molecules

Ipatasertib
(AKT inhibitor)

(GDC-0068, RG7440)a

Find out more about how ipatasertib, an Akt inhibitor, is proposed to work.

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Small Molecules
  • Hematology
  • T-cell Bispecific Antibodies

Atezolizumab
(anti-PDL1 MAb)

(RG7446)

 

  • Lung
  • Gastrointestinal
  • Genitourinary
  • Monoclonal Antibodies

Cobimetinib
(MEK inhibitor)

(RG7421)e

 

  • Breast
  • Gastrointestinal
  • Hematology
  • Solid Tumor
  • Small Molecules

Entrectinib

(ROS1/TRK inhibitor)

(RXDX-101, RG6268)b

 

  • Lung
  • Pan Tumor
  • Small Molecules

Individualized NeoAntigen Specific Immunotherapy (iNeST)

(RG6180)g

 

  • Melanoma
  • Individualized neoantigen specific therapy
Page Error

An error occurred while loading this portion of content. We are resolving this issue and apologize for the inconvenience.

Please check back soon for an update.

Tiragolumab
(anti-TIGIT MAb)

(MTIG7192A, RG6058)

 

  • Lung
  • Monoclonal Antibodies

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)d

 

  • Breast
  • Hematology
  • Small Molecules

Phase I

  • Gastrointestinal
  • Solid Tumor
  • T-cell Bispecific Antibodies
  • Hematology
  • Small Molecules

Ipatasertib
(AKT inhibitor)

(GDC-0068, RG7440)a

Find out more about how ipatasertib, an Akt inhibitor, is proposed to work.

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Small Molecules
  • Hematology
  • T-cell Bispecific Antibodies

Atezolizumab
(anti-PDL1 MAb)

(RG7446)

 

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Gynecologic
  • Head and Neck
  • Hematology
  • Melanoma
  • Monoclonal Antibodies
  • Solid Tumor

Bevacizumab
(anti-VEGF MAb)

 

  • Gastrointestinal
  • Head and Neck
  • Monoclonal Antibodies

CD19x4-1BBL

(RG6076)

  • Hematology
  • T-cell Bispecific Antibodies

Cobimetinib
(MEK inhibitor)

(RG7421)e

 

  • Gastrointestinal
  • Genitourinary
  • Head and Neck
  • Hematology
  • Small Molecules

Codrituzumab
(anti-glypican 3 MAb)

(CHU)f

 

  • Gastrointestinal
  • Monoclonal Antibodies

Entrectinib

(ROS1/TRK inhibitor)

(RXDX-101, RG6268)b

 

  • Lung
  • Pan Tumor
  • Solid Tumor
  • Small Molecules

FAP-4-1BBL FP

(RG7827)

 

  • Solid Tumor
  • Monoclonal Antibodies

FAP-IL2v FP

(RG7461)

 

  • Breast
  • Gastrointestinal
  • Genitourinary
  • Gynecologic
  • Head and Neck
  • Lung
  • Solid Tumor
  • Monoclonal Antibodies
  • Melanoma

Glypican-3 x CD3

(CHU)f

 

  • Solid Tumor
  • T-cell Bispecific Antibodies

HER2 x CD3

(RG6194)

 

  • Breast
  • Solid Tumor
  • T-cell Bispecific Antibodies

Individualized NeoAntigen Specific Immunotherapy (iNeST)

(RG6180)g

 

  • Solid Tumor
  • Individualized neoantigen specific therapy

Monoclonal antibody

(RG6160)

 

  • Hematology
  • Monoclonal Antibodies

Pan-RAF inhibitor

(RG6185)

 

  • Solid Tumor
  • Small Molecules
  • Lung
  • Melanoma
  • Solid Tumor
  • T-cell Bispecific Antibodies

PI3K inhibitor

(GDC-0077, RG6114)

 

  • Breast
  • Solid Tumor
  • Small Molecules

Raf/MEK dual inhibitor

(CHU)f

 

  • Solid Tumor
  • Small Molecules

Selective estrogen receptor degrader (SERD) 3

(GDC-9545, RG6171)

 

  • Breast
  • Small Molecules

Selicrelumab
(CD40 MAb)

(RG7876)

 

  • Gynecologic
  • Head and Neck
  • Lung
  • Solid Tumor
  • Monoclonal Antibodies

Tiragolumab

(anti-TIGIT MAb)

(MTIG7192A, RG6058)

 

  • Solid Tumor
  • Hematology
  • Monoclonal Antibodies

Vanucizumab
(ANG2/VEGF biMAb)

(RG7221)

 

  • Gastrointestinal
  • Solid Tumor
  • Monoclonal Antibodies

Venetoclax
(BCL-2 inhibitor)

(ABT-199/GDC-0199, RG7601)d

 

  • Hematology
  • Small Molecules

aDeveloped in collaboration with Array BioPharma. bIgnyta, Inc acquisition. cDeveloped in collaboration with Seattle Genetics. dJoint project with AbbVie. eDeveloped in collaboration with Exelixis. fDeveloped in collaboration with Chugai. gDeveloped in collaboration with BioNTech.

Reference

  1. Roche third-quarter results 2019 presentation. https://www.roche.com/dam/jcr:856bb040-90a8-48ec-bbbc-e014f02541f1/en/irp191016-a.pdf. Accessed October 23, 2019.